Allergan

How generic cyclosporine might affect optometry
How generic cyclosporine might affect optometryI foresee every dry eye script I write to be “changed” to generic cyclosporine. This means optometrists will be straddled with more burdensome prior authorizations and delays for the patients.
Using contact lenses to steepen the cornea post surgeryThe over response of LASIK patients is not a common event, but it does happen. CLAPIKS provides a straightforward and practical approach to help patients through this healing period.
Substance P: Dry eye and allergy’s mixed signal or missing link?Inflammation may lead to heightened peripheral sensitization and stimulation through a developing concept in which neuroimmune cross-talk causes the confounding interplay of both signs and symptoms in dry eye and allergic disease.
Targeting dry eye in glaucoma patients
Targeting dry eye in glaucoma patientsA poor ocular surface is a common condition in glaucoma patients due to the incidence of dry eye, age, and use of benzalkonium chloride (BAK). Poor compliance with glaucoma therapy can result. Use of point-of-care testing can help identify patients with a poor ocular surface and drive treatment decisions. Treatment options, including surgical, are discussed.
Uro Pipeline: Supplemental application submitted for advanced RCC treatmentOther pipeline developments include an agent to control pain in IC/BPS patients, an antibody to treat prostate and bladder cancer, an injectable OAB treatment, and more.
Reviewing anterior segment ARVO 2017 postersSo much basic science research is presented at this meeting, and most of it will be years before it makes its way to clinical trials. Let’s concentrate on research that might be of use to us in the exam room very soon.
Epicutaneous immunotherapy may transform allergy treatment
Epicutaneous immunotherapy may transform allergy treatmentAs an allergy sufferer myself, I tend to pore over the journals and literature to learn what new exciting technologies may be on the horizon. When I came across epicutaneous immunotherapy (EPIT), my mind went in a multitude of different directions about the endless possibilities for both systemic and ocular allergy management.
Glaucoma, dry eye drugs center of pharmaceutical opportunitiesThe pharma drought is coming to a close. After decades of same-old medications for glaucoma and ocular surface disease, a series of new agents with new mechanisms of action (MOA) are moving toward marketing approval.
Growing number of devices set to transform glaucoma treatmentMinimally invasive glaucoma surgery (MIGS) is the latest development in the treatment of glaucoma. With two MIGS devices already approved in the United States, there are a variety of novel devices that have the potential to transform the treatment of glaucoma.
Evolution in glaucoma surgery mounting with MIGS proceduresAn expanding armamentarium of minimally invasive and micro-invasive glaucoma surgery procedures is transforming glaucoma management.